ClinicalTrials.gg
CompletedNCT06435676Updated May 22, 2025

A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects

A Phase 1 interventional study of HRS9531 and Placebo in Overweight or Obesity; Type 2 Diabetes, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-22.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing ribupatide in Obesity — 2 open to participants now, 9 under way, 6 of them phase 3. ribupatide · Obesity.

Enrollment
12th of 16
72 · median 142
Started
2024
with 2 others
Phase 1
5 of 16
1 open now
Registered
5th of 16
by date
Lead sponsor
9 of 16
Fujian Shengdi Pharmaceutical Co., Ltd.

Among the 16 studies testing ribupatide in Obesity, this one is the 12th largest by enrollment, is one of 3 that started in 2024, is one of 5 in phase 1, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 16 studies testing ribupatide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ribupatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing ribupatide in Obesity, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS9531tablets in healthy subjects.

03

Conditions studied

  • Overweight or Obesity; Type 2 Diabetes

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 72 is close to the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the trial procedures, be able and willing to provide a written .
  2. 18-55 years of age at the time of signing informed consent.
  3. SAD stage: Body weight ≥50 kg,19.0 ≤≤ 35.0 kg/m2 at screening visit. MAD stage: 24.0 ≤BMI≤ 35.0 kg/m2 at screening visit.
  4. Subjects with good general health, no abnormalities.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected to trial product(s) or related products.
  2. With previous major organ diseases, including but not limited to neuropsychiatric, cardiovascular, digestive, respiratory, urinary, endocrine, blood, immune and other diseases, are judged by researchers to be unsuitable for the study.
  3. Abnormal and blood pressure at screening.
  4. Blood donation within 1 month prior to screening, or blood donation ≥400 mL or blood loss ≥400 mL within 3 months prior to screening.
  5. Participation in other clinical trials.
  6. Presence of any clinically significant results in examination at screening visit.
  7. surface antigen (HBsAg), antibody detection, treponema pallidum specific antibody detection, virus antibody (HCVAb) positive.
  8. Presence of - clinically significant results.
  9. Known or suspected history of drug abuse or drug abuse, or urine drug screening test during the screening periodThose who are positive.
  10. Addiction to tobacco and alcohol.
  11. In the opinion of the investigator, there are any other conditions that interfere with the evaluation of the results of the trial or are not suitable for participation of this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    SAD Stage: HRS9531

    Administered po once

    Drug: HRS9531

  • Placebo comparator
    SAD Stage: placebo

    Administered po once

    Drug: Placebo

  • Experimental
    MAD Stage: HRS9531

    Administered po for multiple dose

    Drug: HRS9531

  • Placebo comparator
    MAD Stage: placebo

    Administered po for multiple dose

    Drug: Placebo

Interventions

  • Single dose escalation of HRS9531 tablets in healthy subjects

  • DrugPlacebo

    Single dose of placebo in healthy adults

  • Multiple dose escalation of HRS9531 tablets in healthy subjects

  • DrugPlacebo

    Multiple dose of placebo in healthy adults

07

What researchers measure

Primary outcomes

  1. SAD Stage: Number of Adverse Events

    Time frame: 36 days

  2. MAD Stage: Number of Adverse Events

    Time frame: 63 days

Secondary outcomes

  1. Plasma Concentration-Time to Peak (Tmax) of HRS9531

    Tmax of a single dose of HRS9531 tablets

    Time frame: 36 days

  2. Area Under the Plasma Concentration-Time Curve (AUC) of HRS9531

    AUC of a single dose of HRS9531 tablets

    Time frame: 36 days

  3. Immunogenicity qualitative

    anti-HRS9531 antibody

    Time frame: 36 days

  4. Plasma Concentration-Time to Peak (Tmax) of HRS9531

    Tmax of multiple dose of HRS9531 tablets

    Time frame: 63 days

  5. Area Under the Plasma Concentration-Time Curve (AUC) of HRS9531

    AUC of multiple dose of HRS9531 tablets

    Time frame: 63 days

  6. Glucose

    fasting plasma glucose

    Time frame: 35 days

  7. Immunogenicity qualitative

    anti-HRS9531 antibody

    Time frame: 63 days

08

Study locations

1 site
  • The Second Hospital Of Anhui medical University
    Hefei, Anhui 230601, China
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Oct 2024, 4 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2024
First posted
May 30, 2024
StartActual
Jun 4, 2024
Primary completionActual
Oct 8, 2024
CompletionActual
Oct 8, 2024
Last update
May 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06435676
Responsible party
Sponsor
First posted
May 30, 2024
Start date
Jun 4, 2024
Primary completion
Oct 8, 2024
Completion
Oct 8, 2024
Last update
May 22, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion